Annual EBITDA
-$9.65 M
+$8.83 M+47.78%
31 December 2023
Summary:
Cyclerion Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$9.65 million, with the most recent change of +$8.83 million (+47.78%) on 31 December 2023. During the last 3 years, it has risen by +$70.99 million (+88.04%). CYCN annual EBITDA is now at all-time high.CYCN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.13 M
+$256.00 K+18.50%
30 September 2024
Summary:
Cyclerion Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.13 million, with the most recent change of +$256.00 thousand (+18.50%) on 30 September 2024. Over the past year, it has increased by +$1.58 million (+58.39%). CYCN quarterly EBITDA is now at all-time high.CYCN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$5.92 M
+$1.58 M+21.08%
30 September 2024
Summary:
Cyclerion Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$5.92 million, with the most recent change of +$1.58 million (+21.08%) on 30 September 2024. Over the past year, it has increased by +$6.38 million (+51.85%). CYCN TTM EBITDA is now at all-time high.CYCN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CYCN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +47.8% | +58.4% | +51.9% |
| 3 y3 years | +88.0% | +90.0% | +89.8% |
| 5 y5 years | +91.5% | +95.9% | +95.3% |
CYCN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +88.0% | at high | +92.1% | at high | +89.8% |
| 5 y | 5 years | at high | +92.1% | at high | +95.9% | at high | +95.3% |
| alltime | all time | at high | +92.1% | at high | +96.9% | at high | +95.4% |
Cyclerion Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.13 M(-18.5%) | -$5.92 M(-21.1%) |
| June 2024 | - | -$1.38 M(-14.5%) | -$7.51 M(-6.0%) |
| Mar 2024 | - | -$1.62 M(-9.9%) | -$7.99 M(-17.2%) |
| Dec 2023 | -$9.65 M(-47.8%) | -$1.79 M(-33.8%) | -$9.65 M(-21.6%) |
| Sept 2023 | - | -$2.71 M(+45.4%) | -$12.31 M(-12.8%) |
| June 2023 | - | -$1.86 M(-43.1%) | -$14.11 M(-45.0%) |
| Mar 2023 | - | -$3.27 M(-26.5%) | -$25.66 M(-27.3%) |
| Dec 2022 | -$18.48 M(-65.7%) | -$4.46 M(-1.4%) | -$35.33 M(-21.8%) |
| Sept 2022 | - | -$4.52 M(-66.3%) | -$45.16 M(-13.0%) |
| June 2022 | - | -$13.42 M(+3.7%) | -$51.88 M(-3.3%) |
| Mar 2022 | - | -$12.94 M(-9.5%) | -$53.64 M(-0.4%) |
| Dec 2021 | -$53.84 M | -$14.29 M(+27.2%) | -$53.84 M(-7.7%) |
| Sept 2021 | - | -$11.24 M(-26.0%) | -$58.30 M(-14.0%) |
| June 2021 | - | -$15.18 M(+15.5%) | -$67.82 M(-5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$13.14 M(-30.0%) | -$71.70 M(-11.1%) |
| Dec 2020 | -$80.64 M(-34.1%) | -$18.75 M(-9.6%) | -$80.64 M(-8.2%) |
| Sept 2020 | - | -$20.75 M(+8.9%) | -$87.82 M(-7.0%) |
| June 2020 | - | -$19.06 M(-13.7%) | -$94.39 M(-12.2%) |
| Mar 2020 | - | -$22.08 M(-14.9%) | -$107.56 M(-12.1%) |
| Dec 2019 | -$122.34 M(+7.6%) | -$25.93 M(-5.1%) | -$122.34 M(-3.6%) |
| Sept 2019 | - | -$27.32 M(-15.2%) | -$126.84 M(-1.3%) |
| June 2019 | - | -$32.23 M(-12.6%) | -$128.47 M(+2.2%) |
| Mar 2019 | - | -$36.86 M(+21.1%) | -$125.65 M(+10.5%) |
| Dec 2018 | -$113.72 M(+23.4%) | -$30.44 M(+5.1%) | -$113.72 M(+36.5%) |
| Sept 2018 | - | -$28.95 M(-1.6%) | -$83.29 M(+53.3%) |
| June 2018 | - | -$29.41 M(+18.0%) | -$54.34 M(+118.0%) |
| Mar 2018 | - | -$24.93 M | -$24.93 M |
| Dec 2017 | -$92.18 M | - | - |
FAQ
- What is Cyclerion Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Cyclerion Therapeutics?
- What is Cyclerion Therapeutics annual EBITDA year-on-year change?
- What is Cyclerion Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Cyclerion Therapeutics?
- What is Cyclerion Therapeutics quarterly EBITDA year-on-year change?
- What is Cyclerion Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Cyclerion Therapeutics?
- What is Cyclerion Therapeutics TTM EBITDA year-on-year change?
What is Cyclerion Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CYCN is -$9.65 M
What is the all time high annual EBITDA for Cyclerion Therapeutics?
Cyclerion Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$9.65 M
What is Cyclerion Therapeutics annual EBITDA year-on-year change?
Over the past year, CYCN annual earnings before interest, taxes, depreciation & amortization has changed by +$8.83 M (+47.78%)
What is Cyclerion Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CYCN is -$1.13 M
What is the all time high quarterly EBITDA for Cyclerion Therapeutics?
Cyclerion Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$1.13 M
What is Cyclerion Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CYCN quarterly earnings before interest, taxes, depreciation & amortization has changed by +$1.58 M (+58.39%)
What is Cyclerion Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CYCN is -$5.92 M
What is the all time high TTM EBITDA for Cyclerion Therapeutics?
Cyclerion Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$5.92 M
What is Cyclerion Therapeutics TTM EBITDA year-on-year change?
Over the past year, CYCN TTM earnings before interest, taxes, depreciation & amortization has changed by +$6.38 M (+51.85%)